First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours

Investigational New Drugs

Volumn 31, Issue 1, 2013, Pages 108-114

  Fujisaka, Yasuhito ^a,d   Onozawa, Yusuke ^b   Kurata, Takayasu ^a,d   Yasui, Hirofumi ^b   Goto, Isao ^a   Yamazaki, Kentaro ^b   Machida, Nozomu ^b   Watanabe, Junichiro ^b   Shimada, Hitoshi ^c   Shi, Xiaojin ^c   Boku, Narikazu ^b,e  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c ASTRAZENECA   (United Kingdom)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AZD0530; Japanese patients; Non receptor tyrosine kinase; Saracatinib; Src inhibition

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; SRC KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FATIGUE; FEMALE; HUMAN; HYPOXIA; INTERNATIONAL NORMALIZED RATIO; JAPAN; JAPANESE; LEUKOPENIA; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BENZODIOXOLES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SRC-FAMILY KINASES;

EID: 84873077594     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9809-7     Document Type: Article

References (18)

1. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513-609
2. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470-480
3. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC (2003) Activated Src Protein Tyrosine Kinase Is Overexpressed in Late-Stage Human Ovarian Cancers*1. Gynecol Oncol 88:73-79
4. Zou D, Yoon HS, Anjomshoaa A, Perez D, Fukuzawa R, Guilford P, Humar B (2009) Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Res 11:R45
5. Talamonti MS, Roh MS, Curley SA, Gallick G (1993) Increase in activity and level of pp 60c-src in progressive stages of human colorectal cancer. J Clin Invest 91:53-60
6. Gelman I (2011) Src-family tyrosine kinases as therapeutic targets in advanced cancer. Front Biosci (Elite Ed) 3:801-807
7. Trevino JG, Summy JM, Gallick GE (2006) SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem 6:681-687
8. Wheeler DL, Iida M, Dunn EF (2009) The role of Src in solid tumors. Oncologist 14:667-678
9. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A, Otterbein L, Plé PA, Warin N, Costello G (2006) N-(5-Chloro-1,3-benzodioxol-4-yl)-7- [2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4- amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor. J Med Chem 49:6465-6488
10. Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, Elvin P, Boyer B, Carragher N, Plé PA, Bermingham A, Holdgate GA, Ward WH, Hennequin LF, Davies BR, Costello GF (2009) Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 3:248-261
11. Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J (2010) Phase I safety, pharmacokinetics, and inhibition of Src activity study of saracatinib in patients with solid tumors. Clin Cancer Res 16:4876-4883
12. Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ (2009) Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol 5:243-257
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 92:205-216
14. Aamdal S, Boven E, de Vries E, Pujade-Lauraine E, Freyer G, Jones R, Prahladan M, Emeribe U, Kaye S (2010) Phase I study to assess the safety and tolerability of saracatinib (AZD0530) plus carboplatin (C) and/or paclitaxel (P) in patients with solid tumours. Ann Oncol 21(Suppl. 8):(abstract viii171)
15. Poole C, Lisyanskaya A, Rodenhuis S, Kristensen G, Pujade Lauraine E, Cantarini M, Emeribe U, Stuart M, Ray-Coquard I (2010) A randomized phase II clinical trial of the Src inhibitor saracatinib (AZD0530) and carboplatin +paclitaxel (C+P) versus C+P in patients (pts) with advanced platinum-sensitive epithelial ovarian cancer (EOC). Ann Oncol 21(Suppl 8):(abstract 972O)
16. Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer (SaPPrOC) Study. http://clinicaltrials.gov/ct2/show/NCT01196741. Accessed 1 February 2012
17. Stegmeier F, Warmuth M, Sellers WR, Dorsch M (2010) Targeted cancer therapies in the twenty-first century: Lessons from imatinib. Clin Pharmacol Ther 87:543-552
18. Gonzalez-Angulo AM, Hennessy BT, Mills GB (2010) Future of personalized medicine in oncology: A systems biology approach. J Clin Oncol 28:2777-2783